Success Story
Trace Biosciences Fluorescent Imaging Agent Achieves IND Status
Trace Biosciences (https://www.trace-bio.com/), a spinout of Oregon Health and Science University, was a finalist at the 2023 Angel Oregon Bio investment conference and became an ONAMI investee immediately afterward, based on its outstanding scientific pedigree, contribution to human health and highly capable management team.
Since that time it has attracted significant additional funding in the form of grants and investments.
In December 2025, it reached a critical milestone: FDA approval of its Investigational New Drug application for LGW16-03, the company's first nerve-specific fluorescent imaging agent.
LGW16-03 is designed to selectively bind peripheral nerves and emit a near-infrared fluorescent signal, allowing surgeons to visualize critical nerve structures in real time during surgery even when buried beneath tissues.
Read the full announcement at:
